DNA methylome combined with chromosome cluster-oriented analysis provides an early signature for cutaneous melanoma aggressiveness

  1. Arnaud Carrier
  2. Cécile Desjobert
  3. Loic Ponger
  4. Laurence Lamant
  5. Matias Bustos
  6. Jorge Torres-Ferreira
  7. Rui Henrique
  8. Carmen Jeronimo
  9. Luisa Lanfrancone
  10. Audrey Delmas
  11. Gilles Favre
  12. Antoine Delaunay
  13. Florence Busato
  14. Dave SB Hoon
  15. Jorg Tost
  16. Chantal Etievant
  17. Joëlle Riond
  18. Paola B Arimondo  Is a corresponding author
  1. CNRS-Pierre Fabre, France
  2. CNRS UMR 7196, INSERM U1154, France
  3. UMR 1037, INSERM, Université Toulouse III Paul Sabatier, France
  4. Providence Saint John's Health Center, United States
  5. Portuguese Oncology Institute, Portugal
  6. Instituto Europeo di Oncologia, Italy
  7. Fondation Jean Dausset-CEPH, France
  8. CNRS, CEA-Institut de Biologie François Jacob, France
  9. Institut Pasteur, CNRS UMR 3523, France

Abstract

Aberrant DNA methylation is a well‑known feature of tumours and has been associated with metastatic melanoma. However, since melanoma cells are highly heterogeneous, it has been challenging to use affected genes to predict tumour aggressiveness, metastatic evolution, and patients' outcomes. We hypothesized that common aggressive hypermethylation signatures should emerge early in tumorigenesis and should be shared in aggressive cells, independent of the physiological context under which this trait arises. We compared paired melanoma cell lines with the following properties: (i) each pair comprises one aggressive counterpart and its parental cell line, and (ii) the aggressive cell lines were each obtained from different host and their environment (human, rat, and mouse), though starting from the same parent cell line. Next, we developed a multi-step genomic pipeline that combines the DNA methylome profile with a chromosome cluster-oriented analysis. A total of 229 differentially hypermethylated genes were commonly found in the aggressive cell lines. Genome localization analysis revealed hypermethylation peaks and clusters, identifying eight hypermethylated gene promoters for validation in tissues from melanoma patients. Five CpG identified in primary melanoma tissues were transformed into a DNA methylation score that can predict survival (Log-rank test, p=0.0008). This strategy is potentially universally applicable to other diseases involving DNA methylation alterations.

Data availability

Sequencing data have been deposited in GEO under accession code GSE155856R-scripts are available in Source Code 1 fileThe datasets supporting the conclusions of this article are included within the article and the following Supplementary files

The following data sets were generated

Article and author information

Author details

  1. Arnaud Carrier

    Unité de Service et de Recherche USR 3388, CNRS-Pierre Fabre, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Cécile Desjobert

    Unité de Service et de Recherche USR 3388, CNRS-Pierre Fabre, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Loic Ponger

    CNRS UMR 7196, INSERM U1154, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Laurence Lamant

    Cancer Research Center of Toulouse, UMR 1037, INSERM, Université Toulouse III Paul Sabatier, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Matias Bustos

    Department of Translational Molecular Medicine, Providence Saint John's Health Center, Santa Monica, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Jorge Torres-Ferreira

    Cancer Biology and Epigenetics Group, Portuguese Oncology Institute, Porto, Portugal
    Competing interests
    The authors declare that no competing interests exist.
  7. Rui Henrique

    Cancer Biology and Epigenetics Group, Portuguese Oncology Institute, Porto, Portugal
    Competing interests
    The authors declare that no competing interests exist.
  8. Carmen Jeronimo

    Cancer Biology and Epigenetics Group, Portuguese Oncology Institute, Porto, Portugal
    Competing interests
    The authors declare that no competing interests exist.
  9. Luisa Lanfrancone

    Department of Experimental Oncology, Instituto Europeo di Oncologia, Milan, Italy
    Competing interests
    The authors declare that no competing interests exist.
  10. Audrey Delmas

    Cancer Research Center of Toulouse, UMR 1037, INSERM, Université Toulouse III Paul Sabatier, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  11. Gilles Favre

    Cancer Research Center of Toulouse, UMR 1037, INSERM, Université Toulouse III Paul Sabatier, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  12. Antoine Delaunay

    Laboratory for Functional Genomics, Fondation Jean Dausset-CEPH, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  13. Florence Busato

    Laboratory for Epigenetics and Environment, CNRS, CEA-Institut de Biologie François Jacob, Evry, France
    Competing interests
    The authors declare that no competing interests exist.
  14. Dave SB Hoon

    Department of Translational Molecular Medicine, Providence Saint John's Health Center, Santa Monica, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Jorg Tost

    Laboratory for Epigenetics and Environment, CNRS, CEA-Institut de Biologie François Jacob, Evry, France
    Competing interests
    The authors declare that no competing interests exist.
  16. Chantal Etievant

    Unité de Service et de Recherche USR 3388, CNRS-Pierre Fabre, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  17. Joëlle Riond

    Unité de Service et de Recherche USR 3388, CNRS-Pierre Fabre, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  18. Paola B Arimondo

    Department Structural Biology and Chemistry, Institut Pasteur, CNRS UMR 3523, Paris, France
    For correspondence
    paola.arimondo@cnrs.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5175-4396

Funding

CNRS (ATIP to PBA)

  • Paola B Arimondo

Region Midi Pyrenees-CNRS (Equipe d'excellence to PBA)

  • Paola B Arimondo

Region Midi Pyrenees - CNRS (FEDER to PBA)

  • Paola B Arimondo

Fondation InnaBioSante (EpAM to PBA)

  • Paola B Arimondo

Adelson Medical Research Foundation (grant to DH and MB)

  • Dave SB Hoon

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Tumour samples from melanoma patients were obtained from the tumour tissue bank at the Department of Pathology, IUCT-O Toulouse Hospital (France). The study was carried out in accordance with the institutional review board-approved protocols (CRB, AC-2013-1955) and the procedures followed were in accordance with the Helsinki Declaration.This study was approved by the institutional ethics committee of IPO Porto (CES-IPOP-FG13/2016).

Copyright

© 2022, Carrier et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 605
    views
  • 168
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Arnaud Carrier
  2. Cécile Desjobert
  3. Loic Ponger
  4. Laurence Lamant
  5. Matias Bustos
  6. Jorge Torres-Ferreira
  7. Rui Henrique
  8. Carmen Jeronimo
  9. Luisa Lanfrancone
  10. Audrey Delmas
  11. Gilles Favre
  12. Antoine Delaunay
  13. Florence Busato
  14. Dave SB Hoon
  15. Jorg Tost
  16. Chantal Etievant
  17. Joëlle Riond
  18. Paola B Arimondo
(2022)
DNA methylome combined with chromosome cluster-oriented analysis provides an early signature for cutaneous melanoma aggressiveness
eLife 11:e78587.
https://doi.org/10.7554/eLife.78587

Share this article

https://doi.org/10.7554/eLife.78587

Further reading

    1. Cancer Biology
    2. Immunology and Inflammation
    Sofia V Krasik, Ekaterina A Bryushkova ... Ekaterina O Serebrovskaya
    Research Article

    The current understanding of humoral immune response in cancer patients suggests that tumors may be infiltrated with diffuse B cells of extra-tumoral origin or may develop organized lymphoid structures, where somatic hypermutation and antigen-driven selection occur locally. These processes are believed to be significantly influenced by the tumor microenvironment through secretory factors and biased cell-cell interactions. To explore the manifestation of this influence, we used deep unbiased immunoglobulin profiling and systematically characterized the relationships between B cells in circulation, draining lymph nodes (draining LNs), and tumors in 14 patients with three human cancers. We demonstrated that draining LNs are differentially involved in the interaction with the tumor site, and that significant heterogeneity exists even between different parts of a single lymph node (LN). Next, we confirmed and elaborated upon previous observations regarding intratumoral immunoglobulin heterogeneity. We identified B cell receptor (BCR) clonotypes that were expanded in tumors relative to draining LNs and blood and observed that these tumor-expanded clonotypes were less hypermutated than non-expanded (ubiquitous) clonotypes. Furthermore, we observed a shift in the properties of complementarity-determining region 3 of the BCR heavy chain (CDR-H3) towards less mature and less specific BCR repertoire in tumor-infiltrating B-cells compared to circulating B-cells, which may indicate less stringent control for antibody-producing B cell development in tumor microenvironment (TME). In addition, we found repertoire-level evidence that B-cells may be selected according to their CDR-H3 physicochemical properties before they activate somatic hypermutation (SHM). Altogether, our work outlines a broad picture of the differences in the tumor BCR repertoire relative to non-tumor tissues and points to the unexpected features of the SHM process.

    1. Cancer Biology
    2. Computational and Systems Biology
    Rosalyn W Sayaman, Masaru Miyano ... Mark A LaBarge
    Research Article Updated

    Effects from aging in single cells are heterogenous, whereas at the organ- and tissue-levels aging phenotypes tend to appear as stereotypical changes. The mammary epithelium is a bilayer of two major phenotypically and functionally distinct cell lineages: luminal epithelial and myoepithelial cells. Mammary luminal epithelia exhibit substantial stereotypical changes with age that merit attention because these cells are the putative cells-of-origin for breast cancers. We hypothesize that effects from aging that impinge upon maintenance of lineage fidelity increase susceptibility to cancer initiation. We generated and analyzed transcriptomes from primary luminal epithelial and myoepithelial cells from younger <30 (y)ears old and older >55 y women. In addition to age-dependent directional changes in gene expression, we observed increased transcriptional variance with age that contributed to genome-wide loss of lineage fidelity. Age-dependent variant responses were common to both lineages, whereas directional changes were almost exclusively detected in luminal epithelia and involved altered regulation of chromatin and genome organizers such as SATB1. Epithelial expression variance of gap junction protein GJB6 increased with age, and modulation of GJB6 expression in heterochronous co-cultures revealed that it provided a communication conduit from myoepithelial cells that drove directional change in luminal cells. Age-dependent luminal transcriptomes comprised a prominent signal that could be detected in bulk tissue during aging and transition into cancers. A machine learning classifier based on luminal-specific aging distinguished normal from cancer tissue and was highly predictive of breast cancer subtype. We speculate that luminal epithelia are the ultimate site of integration of the variant responses to aging in their surrounding tissue, and that their emergent phenotype both endows cells with the ability to become cancer-cells-of-origin and represents a biosensor that presages cancer susceptibility.